ClinicalTrials.gg
RecruitingNCT05633654Updated Nov 4, 2026

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

A Phase 3 interventional study of Sacituzumab govitecan-hziy (SG) and Pembrolizumab in Triple Negative Breast Cancer, sponsored by Gilead Sciences. Recruiting at 378 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Nov 4, 2026First site in JapanSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,514
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms — 11 open to participants now, 18 under way, 6 of them phase 3. sacituzumab govitecan · Triple Negative Breast Neoplasms.

Planned enrollment
Largest of 21
1,514 · median 138
Started
2022
with 2 others
Phase 3
6 of 21
2 open now
Primary completion
2027-06
later than 7 of 17 live
Registered
13th of 21
by date
Lead sponsor
8 of 21
Gilead Sciences

Among the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, this one has the largest planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 7 of the 17 other live ones, and was the 13th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • AFT-65
  • GBG 119
  • NSABP B-63
  • OptimICE-RD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age > 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after therapy and surgery:

    • TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) ≤ 10%, human epidermal growth factor receptor 2 ()-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).
  • Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.
  • Submission of both pre-neoadjuvant treatment diagnostic and resected residual invasive disease tissue.
  • (ECOG) performance status 0-1.
  • Individuals must have received appropriate radiotherapy aligned with local/institutional practice and have recovered prior to starting study treatment.
  • Adequate organ function.

Key Exclusion Criteria:

  • Stage IV () breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.
  • Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior endocrine therapy for > 4 weeks or planned concurrent endocrine therapy while receiving on-study treatment.
  • Evidence of recurrent disease following preoperative therapy and surgery.
  • Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.
  • Individuals with germline breast cancer gene (BRCA) mutations.
  • Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or (LVEF) of \< 50%
  • Active serious infections requiring anti-microbial therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,514 participants (estimated)

Study arms

  • Experimental
    Sacituzumab govitecan-hziy (SG) + Pembrolizumab

    Participants will receive SG 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles. Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death.

    Drug: Sacituzumab govitecan-hziy (SG) · Drug: Pembrolizumab

  • Active comparator
    Treatment of Physician's Choice (TPC): Pembrolizumab or Pembrolizumab + Capecitabine

    Participants will receive one of the following TPC regimens determined prior to randomization: * Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles OR * Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles and capecitabine 1000 mg/m\^2 orally twice daily on Days 1 through 14 of 21-day cycles for 8 cycles. Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death.

    Drug: Pembrolizumab · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival (iDFS)

    iDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, invasive contralateral breast cancer.

    Time frame: Up to 60 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause.

    Time frame: Up to 96 months

  2. Distant Disease-free Survival (dDFS)

    dDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): distant recurrence, or second primary invasive cancer.

    Time frame: Up to 60 months

  3. Recurrence-free Survival (RFS)

    RFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence.

    Time frame: Up to 60 months

  4. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 38 months plus 30 days

  5. Percentage of Participants Experiencing Laboratory Abnormalities

    Time frame: First dose date up to 38 months plus 30 days

  6. Time to Worsening (TTW) of Quality of Life (QoL) Based on Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) Trial Outcome Index (TOI) Scores

    TTW of FACT-B TOI scores will be analyzed for each index, the TTW of FACT-B scores will be measured from the randomization date and to the time the participants first experienced a first score of worsening.

    Time frame: Up to 60 months

07

Study locations

290 of 378 sites recruiting
  • Alabama Oncology
    Birmingham, Alabama 35243, United States
    Recruiting
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
    Recruiting
  • Palo Verde Hematology Oncology
    Glendale, Arizona 85304, United States
    Recruiting
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Arizona Oncology Associates
    Prescott Valley, Arizona 86314, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alta Bates Summit Medical Center
    Berkeley, California 94704, United States
    Recruiting
  • Community Cancer Institute
    Clovis, California 93611, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • PIH Health Whittier Hospital
    Downey, California 90241, United States
    Recruiting
  • Compassionate Cancer Care Medical Group - Inc
    Fountain Valley, California 92708, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Los Angeles Cancer Network
    Los Angeles, California 90017, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Cedars-Sinai Cancer at Beverly Hills
    Los Angeles, California 90048, United States
    Recruiting
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
  • Emad Ibrahim, MD, INC
    Redlands, California 92373, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sutter Institute for Medical Research
    Sacramento, California 95816, United States
    Recruiting
  • City of Hope (Duarte)
    San Francisco, California 94143, United States
    Recruiting
  • UCSF Medical Center
    San Francisco, California 94143, United States
    Recruiting
  • Sansum Clinic
    Santa Barbara, California 93105, United States
    Recruiting
  • Stockton Hematology Oncology Medical Group
    Stockton, California 95204, United States
    Recruiting
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Norwalk Hospital
    Danbury, Connecticut 06810, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Stamford Hospital
    Stamford, Connecticut 06902, United States
    Recruiting
  • MedStar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Morton Plant Hospital - Bay Care
    Clearwater, Florida 00337, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Florida
    Gainesville, Florida 32610, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
    Recruiting
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
    Recruiting
  • Jupiter Medical Center
    Jupiter, Florida 33458, United States
    Recruiting
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
    Recruiting
  • Midland Florida Clinical Research Center, L
    Orange City, Florida 32763, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Orlando Health
    Orlando, Florida 32806, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cancer Care Centers of Brevard, Inc
    Palm Bay, Florida 32909, United States
    Recruiting
  • Memorial Healthcare System
    Pembroke Pines, Florida 33028, United States
    Recruiting
  • Sacred Heart Medical Oncology Group
    Pensacola, Florida 32504, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sylvester Comprehensive Cancer Center
    Plantation, Florida 33324, United States
    Recruiting
  • Cleveland Clinic Florida, Martin North Hospital
    Stuart, Florida 34994, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. Joseph's Hospital
    Tampa, Florida 33614, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Weston Hospital
    Weston, Florida 33331, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Cancer & Blood Center, LLC.
    Athens, Georgia 30607, United States
    Recruiting
  • Piedmont Cancer Institute
    Atlanta, Georgia 30318, United States
    Recruiting
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
    Recruiting
  • Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta
    Newnan, Georgia 30265, United States
    Recruiting
  • Pearlman Cancer Center
    Valdosta, Georgia 31602, United States
    Recruiting
  • St Lukes Mountain States Tumor Institute
    Boise, Idaho 83712, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Kootenai Health
    Coeur d'Alene, Idaho 83814, United States
    Recruiting
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
    Recruiting
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
  • University of Illinois
    Chicago, Illinois 60612, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • NorthShore University Healthsystem
    Evanston, Illinois 60201, United States
    Recruiting
  • Edward Hospital
    Naperville, Illinois 60540, United States
    Recruiting
  • West Suburban Medical Center- River Forest
    River Forest, Illinois 60305, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Edward H. Kaplan MD & Associates - Hematology/Oncology of the North Shore
    Skokie, Illinois 60076, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Springfield Clinic LLP
    Springfield, Illinois 62702, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Carle Cancer Center
    Urbana, Illinois 61801, United States
    Recruiting
  • Franciscan Health Indianapolis
    Indianapolis, Indiana 46237, United States
    Recruiting
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46260, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • IU Health Arnett Hospital
    Lafayette, Indiana 47904, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Franciscan Health Munster
    Munster, Indiana 46321, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mercy Medical Center
    Cedar Rapids, Iowa 52403, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mission Cancer & Blood - John Stoddard Cancer Center
    Des Moines, Iowa 50309, United States
    Recruiting
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    Recruiting
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
    Recruiting
  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Norton Healthcare, Inc.
    Louisville, Kentucky 40207, United States
    Recruiting
  • Mercy Health
    Paducah, Kentucky 42003, United States
    Recruiting
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Medical Center - New Orleans
    New Orleans, Louisiana 70122, United States
    Recruiting
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
    Recruiting
  • Sinai Hospital of Baltimore, Inc.
    Baltimore, Maryland 21215, United States
    Recruiting
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
    Recruiting
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
    Recruiting
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • James M Stockman Cancer Institute
    Frederick, Maryland 21702, United States
    Recruiting
  • Greater Baltimore Medical Center
    Towson, Maryland 21204, United States
    Recruiting
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Dana-Farber Cancer Institute @Foxborough
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Dana-Farber Cancer Institude at Merrimack Valley
    Methuen, Massachusetts 01844, United States
    Recruiting
  • Dana Farber Cancer Institute @ Milford Regional Hospital
    Milford, Massachusetts 01757, United States
    Recruiting
  • Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital
    South Weymouth, Massachusetts 02190, United States
    Recruiting
  • Baystate Medical Center Inc.
    Springfield, Massachusetts 01199, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Massachusetts Worcester
    Worcester, Massachusetts 01655, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Ascension
    Grosse Pointe Woods, Michigan 48236, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
    Recruiting
  • Ascension Providence Hospital Southfield Cancer Center
    Southfield, Michigan 48075, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Trinity Health St. Joseph Mercy Ann Arbor
    Ypsilanti, Michigan 48197, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Minnesota Oncology Hematology, PA
    Maplewood, Minnesota 55109, United States
    Recruiting
  • Virginia Piper Cancer Center (Allina Health)
    Minneapolis, Minnesota 55407, United States
    Recruiting
  • University of Minnesota Medical Center, Fairview
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
  • Metro Minnesota Community Oncology
    Saint Louis Park, Minnesota 55426, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting

Showing the first 100 of 378 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (+/- capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. PubMed 38922307 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jun 2027, 54 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Dec 12, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed — first site in Japan. 11 sites changed recruiting status (8 now recruiting, 2 now withdrawn, …)
Show 11 sites
  • Kinghorn Cancer Centre · Darlinghurst, AustraliaRecruiting→Withdrawn
  • Rua Padre Germano Mayer, 1949, Hugo Lange, Curitiba, Paraná · Curitiba, BrazilActive, not recruiting→Recruiting
  • Instituto Santa Joana Recife de Ensino e Pesquisa · Recife, BrazilActive, not recruiting→Recruiting
  • Instituto D'Or de Pesquisa e Ensino - RJ · Rio de Janiero, BrazilActive, not recruiting→Recruiting
  • Bei der Marienkirche 6 · Mühlhausen, GermanyNot yet recruiting→Withdrawn
  • University Hospital Limerick · Limerick, IrelandActive, not recruiting→Not yet recruiting
  • Hull University Teaching Hospitals NHS Trust · Cottingham, United KingdomNot yet recruiting→Recruiting
  • The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, United KingdomNot yet recruiting→Recruiting
  • Guy's Hospital · London, United KingdomNot yet recruiting→Recruiting
  • East and North Hertfordshire NHS Trust · Northwood, United KingdomNot yet recruiting→Recruiting
  • Institut Jules Bordet · Anderlecht, BelgiumActive, not recruiting→Recruiting
Show 7 added (4 Japan, 2 Germany, 1 United States)
  • Tufts Medical Center · Boston, United States
  • Klinikum Bremen-Mitte · Bremen, Germany
  • Wilhelm-Epstein-Str. 4 · Frankfurt, Germany
  • Chiba Cancer Center · Chiba, Japan
  • The Cancer Institute Hospital of JFCR · Tokyo, Japan
  • Aichi Cancer Center · Aichi, Japan
  • National Hospital Organization Hokkaido Cancer Center · Sapporo, Japan
Show 1 removed
  • St.-Juergen-Str. 1 · Bremen, Germany
across 2 updates, Oct 13, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added. Institut Jules Bordet is now Recruiting
    Show 2 added (2 Japan)
    • Aichi Cancer Center · Aichi, Japan
    • National Hospital Organization Hokkaido Cancer Center · Sapporo, Japan
    + 1 other change: verification date
  2. Oct 13, 2026
    5 sites added, 1 site removed — first site in Japan. 10 sites changed recruiting status (7 now recruiting, 2 now withdrawn, …)
    Show 10 sites
    • Kinghorn Cancer Centre · Darlinghurst, AustraliaRecruiting→Withdrawn
    • Rua Padre Germano Mayer, 1949, Hugo Lange, Curitiba, Paraná · Curitiba, BrazilActive, not recruiting→Recruiting
    • Instituto Santa Joana Recife de Ensino e Pesquisa · Recife, BrazilActive, not recruiting→Recruiting
    • Instituto D'Or de Pesquisa e Ensino - RJ · Rio de Janiero, BrazilActive, not recruiting→Recruiting
    • Bei der Marienkirche 6 · Mühlhausen, GermanyNot yet recruiting→Withdrawn
    • University Hospital Limerick · Limerick, IrelandActive, not recruiting→Not yet recruiting
    • Hull University Teaching Hospitals NHS Trust · Cottingham, United KingdomNot yet recruiting→Recruiting
    • The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, United KingdomNot yet recruiting→Recruiting
    • Guy's Hospital · London, United KingdomNot yet recruiting→Recruiting
    • East and North Hertfordshire NHS Trust · Northwood, United KingdomNot yet recruiting→Recruiting
    Show 5 added (2 Germany, 2 Japan, 1 United States)
    • Tufts Medical Center · Boston, United States
    • Klinikum Bremen-Mitte · Bremen, Germany
    • Wilhelm-Epstein-Str. 4 · Frankfurt, Germany
    • Chiba Cancer Center · Chiba, Japan
    • The Cancer Institute Hospital of JFCR · Tokyo, Japan
    Show 1 removed
    • St.-Juergen-Str. 1 · Bremen, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05633654
Lead sponsor
Gilead Sciences
Collaborators
Alliance Foundation Trials, LLC., NSABP Foundation Inc, GBG Forschungs GmbH
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Dec 12, 2022
Primary completion
Jun 2027 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion